Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]

近日，由上海交通大学医学院附属第九人民医院（以下简称"上海九院"）口腔正畸科团队与时代天 使合作研发的"数字化青少年小下颌畸形矫形器的研发及产业化"项目，凭借其创新性与卓越的产业化成 果，荣获"上海产学研合作优秀项目奖"一等奖。这一殊荣标志着项目在科研创新、学术推广和成果转化 方面取得了一个里程碑，也彰显了上海九院和时代天使在推动医疗健康产业高质量发展中踔厉前行、踏 实耕耘的精神风貌。 上海九院口腔正畸科房兵教授、时代天使CEO胡杰章 "上海产学研合作优秀项目奖"由上海市科委批准并经国家科技部备案，旨在表彰和鼓励产学研深度 合作、促进技术创新和成果转化。一等奖项目需在技术创新性、产业化成果和社会影响力等方面表现突 出。本次获奖的"数字化青少年小下颌畸形矫形器"项目，正是一次产学研结合、医工交叉的成功实践。 为了解决青少年小下颌畸形这一发病率高、对青少年咬合、容貌、心理健康有重要影响的牙颌面畸 形问题，上海九院与时代天使携手同行，集结了口腔临床医学研究人员、生物力学专家、工程师和产品 研发人员，充分发挥上海九院在口腔医学临床研究方面和时代天使在隐形矫治技术上的优势，深入分析 颌骨生长发育规律和现有器械的局限性， ...

Group 1 - The core issue is the continuous share reduction by the founder of Times Angel, Li Huamin, raising concerns about the company's future prospects [1] - Since its IPO, Li Huamin has reduced her shareholding from 14.26% to 6.37%, indicating a significant lack of confidence in the company's performance [1] - The company's market capitalization has plummeted approximately 88% from its peak of over 80 billion HKD to around 10 billion HKD [1] Group 2 - Times Angel has experienced a decline in net profit for three consecutive years, dropping from 286 million CNY in 2021 to only 10.02 million USD in 2024, indicating a systemic weakening of profitability [2] - The company's current price-to-earnings ratio stands at about 107 times, significantly higher than its competitor Align Technology's 34 times, suggesting that market expectations for future growth are not being met [2] - Despite substantial investments in overseas market expansion, Times Angel reported a loss of approximately 29.7 million USD in international markets for 2024, reflecting ongoing challenges in converting investments into profits [2] Group 3 - The global orthodontic industry is facing significant challenges, as evidenced by Align Technology's stock price drop of 30% due to poor Q2 performance and layoffs, indicating potential market saturation [2] - Times Angel's overseas revenue remains minimal, with high investment costs and long conversion cycles, posing risks amid intense international competition [2] - Industry experts suggest that without a rapid increase in sales to support its valuation, Times Angel may face escalating challenges in the near future [2]

格隆汇8月7日丨时代天使(06699.HK)公告，公司将于2025年8月25日举行董事会会议，藉以（其中包 括）考虑及批准集团截至2025年6月30日止六个月的未经审计中期业绩及其刊发，考虑派发中期股息 （如有），以及处理其他事项。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ANGELALIGN TECHNOLOGY INC. 時代天使科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6699） 董事會召開日期 時代天使科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董 事會」）謹此宣佈，本公司將於2025年8月25日（星期一）舉行董事會會議，藉以 （其中包括）考慮及批准本集團截至2025年6月30日止六個月之未經審計中期業績 及其刊發，考慮派發中期股息（如有），以及處理其他事項。 承董事會命 時代天使科技有限公司 主席 馮岱先生 香港，2025年8月7日 於本公告日期，董事會包括執行董事胡杰章先生、黃琨先生、宋鑫先生及董莉女 士；非執行董事馮岱先生；獨立非執行董事韓小京先生、石子先生及周浩先生。 ...

Core Insights - The invisible orthodontic technology represents a significant breakthrough in modern orthodontics, providing a revolutionary innovation that enhances comfort, aesthetics, and convenience for consumers [1][18] - The market for invisible aligners is expected to grow significantly, with the industry projected to reach approximately 5.41 billion yuan in 2024, driven by increasing consumer demand for oral health and aesthetics [1][18] Industry Overview - Invisible aligners are a type of dental device used to correct misaligned teeth and bite issues, categorized into fixed, removable, invisible, functional, and lingual types [2] - The main types of orthodontic devices currently in the market include metal brackets, ceramic brackets, lingual brackets, and clear aligners, with clear aligners gaining popularity due to their aesthetic appeal and comfort [4][5] Industry Development History - The invisible aligner industry in China has evolved through two phases: initial development from 2001 to 2012 and rapid growth from 2013 to the present, marked by technological advancements and increased market awareness [7] - The approval of the first invisible aligner patent in China in 2006 and the establishment of the first production line in 2007 were pivotal moments that spurred market entry by numerous dental enterprises [7] Market Background - The per capita disposable income of Chinese residents has been steadily increasing, leading to a rise in healthcare spending, which has positively impacted the orthodontic market [9] - Per capita healthcare spending in China increased from 1,165 yuan in 2015 to 2,115 yuan in 2021, with a projected increase to 2,547 yuan in 2024, reflecting a growing focus on oral health [9] Industry Value Chain - The upstream of the invisible aligner industry includes raw materials and equipment, while the midstream involves production and manufacturing, and the downstream focuses on sales channels such as private clinics and dental hospitals [11] Current Industry Status - The orthodontic market in China has shown strong growth, expanding from 21.18 billion yuan in 2015 to an estimated 95.43 billion yuan in 2024, with a compound annual growth rate of 18.21% [15] - The invisible orthodontic market specifically has grown from 1.25 billion yuan in 2015 to 10.5 billion yuan in 2024, with a compound annual growth rate of 26.73% [15] Competitive Landscape - The Chinese invisible aligner market is characterized by a "dual oligopoly" structure, with companies like Times Angel and Invisalign dominating the market, while local brands are rapidly catching up [20] - Key players in the industry include Times Angel, which holds a 70% market share in China, and other emerging brands like Zhengya and Meilike that are focusing on mid-range markets [21][22] Future Trends - The industry is expected to see accelerated technological upgrades and the integration of artificial intelligence and 3D printing, enhancing treatment precision and production efficiency [26] - Market penetration is anticipated to extend from first and second-tier cities to lower-tier markets, with local brands leveraging cost advantages to capture market share [28] - Regulatory policies are expected to evolve, promoting standardization and integration within the industry, while insurance coverage for orthodontic services may enhance accessibility [29]

Group 1: Financial Performance - The company expects to achieve a net profit of $13.4 to $14.8 million in H1 2025, representing a year-on-year growth of 538.1% to 604.8% [1] - The growth in net profit is primarily driven by a low base in H1 2024, continued growth in overseas markets, and lower investment and operating expenses due to delays in establishing overseas production facilities [1] - Revenue projections for 2025 to 2027 are estimated at $318 million, $374 million, and $445 million, with year-on-year growth rates of 18.1%, 17.8%, and 18.8% respectively [3] Group 2: Market Expansion and Strategy - The company has made a strategic investment in the invisible orthodontics brand Shuyaki, acquiring a 35% stake to deepen its presence in emerging markets [2] - The company is focusing on enhancing accessibility to orthodontic services in lower-tier cities and county markets through its investment in Shuyaki, which is recognized for its cost-effective products and digital services [2] - The company has established a highly specialized team in Europe, Asia-Pacific, and the Americas, accelerating its overseas business with a significant increase in international cases from 33,000 in 2023 to 140,700 in 2024, a growth of 326.4% [1] Group 3: Marketing and Brand Influence - The company is expanding its sales and clinical teams strategically based on the development characteristics of different city tiers and is employing diversified marketing strategies to enhance brand influence [3] - Collaborative marketing initiatives include a summer event with Hasbro's My Little Pony in Shanghai, aimed at promoting early orthodontic education and family interaction [3] - The company launched the "Angel KiD Star Plan" in partnership with Xiaohongshu to promote early orthodontic awareness through authoritative reports and expert collaboration [3]

Market Overview - The Hong Kong stock market showed mixed performance with the Hang Seng Index closing at 24,910.63 points, up 0.03% or 8.1 points, with a total turnover of HKD 215.235 billion [1] - The Hang Seng China Enterprises Index fell by 0.21% to 8,932.68 points, while the Hang Seng Tech Index rose by 0.2% to 5,532.17 points [1] - ZheShang International noted that the market fundamentals remain weak, with a cautious outlook on short-term sentiment [1] Blue Chip Performance - BYD Electronics (00285) led blue-chip stocks, rising 6.72% to HKD 37.8, contributing 3.01 points to the Hang Seng Index [2] - Other notable performers included SMIC (00981) up 3.14% and China Shenhua (01088) up 2.99%, while Li Auto-W (02015) fell 5.35% [2] Sector Highlights - Large tech stocks showed mixed results, with Tencent up 1.7% and Alibaba up 0.6%, while Xiaomi fell 0.55% [3] - The "anti-involution" theme gained traction, with paper, coal, and steel stocks generally rising, including a notable increase of over 10% for Nine Dragons Paper [3][4] - New consumption concepts performed well, with Pop Mart (09992) rising 7.87% and Shangmei (02145) up 7.34% [3] Robotics Sector - The robotics sector saw significant gains, with companies like Geekplus (02590) rising 5.68% and MicroPort (02252) up 4.07% [5] - Recent product launches and government initiatives in Shanghai are expected to accelerate the development of the robotics industry [6] Notable Stock Movements - Times Angel (06699) surged 18.29% after announcing a positive earnings forecast for the first half of 2025, expecting a net profit increase of approximately 538.1% to 604.8% [7] - Crystal Technology (02228) rose 12.42% following a significant partnership agreement worth approximately HKD 470 billion [8] - China Shipbuilding Defense (00317) increased by 7.75% due to optimistic profit forecasts based on seasonal factors in the shipbuilding industry [9] - Zhenjiu Lidu (06979) saw a strong performance despite a projected revenue decline, rising 7.89% [10] - Cathay Pacific (00293) fell 9.66% after reporting mid-year earnings that did not meet market expectations [11]

Core Viewpoint - UBS reports that Times Angel (06699) is expected to achieve a net profit of $13.4 million to $14.8 million in the first half of the year, representing a year-on-year growth of 538% to 605%, exceeding market expectations [1] Financial Performance - The significant growth in both local and overseas revenue is anticipated to positively influence investor sentiment [1] - UBS has raised its earnings per share (EPS) forecast for Times Angel by 105% to HKD 1.18, reflecting lower-than-expected operating expenses [1] - Assuming overseas operations reach breakeven by 2027, the EPS forecast for 2027 has been increased by 7% to HKD 2.02 [1] Investment Recommendation - UBS sets a target price of HKD 82 for the stock and reiterates a "Buy" rating [1]

Core Viewpoint - UBS reports that Times Angel (06699) is expected to achieve a net profit of between 13.4 million to 14.8 million USD in the first half of the year, representing a year-on-year growth of 538% to 605%, exceeding market expectations [1] Financial Performance - The significant growth in both local and overseas revenue is anticipated to positively influence investor sentiment [1] - UBS has raised its earnings per share (EPS) forecast for Times Angel by 105% to 1.18 HKD, reflecting lower-than-expected operating expenses [1] - Assuming that overseas business reaches breakeven by 2027, the EPS forecast for 2027 has been increased by 7% to 2.02 HKD [1] Investment Recommendation - UBS sets a target price of 82 HKD for the stock and reiterates a "Buy" rating [1]